A novel approach to reversal of neuromuscular blockade

Minerva Anestesiologica

Volumn 75, Issue 5, 2009, Pages 349-351

  Della Rocca, G ^a,b   Pompei, L ^a  

^a SANTA MARIA DELLA MISERICORDIA UNIVERSITY HOSPITAL   (Italy)

^b NONE   (Italy)

Author keywords

Anesthesia; Neuromuscular blockade; Rocuronium

Indexed keywords

BENZYLISOQUINOLINE DERIVATIVE; NEOSTIGMINE; PLACEBO; PROPOFOL; ROCURONIUM; SEVOFLURANE; SUGAMMADEX; SUXAMETHONIUM; VECURONIUM; ANDROSTANE DERIVATIVE; CHOLINESTERASE INHIBITOR; ETHER DERIVATIVE; GAMMA CYCLODEXTRIN DERIVATIVE; NEUROMUSCULAR BLOCKING AGENT;

CONFERENCE PAPER; DRUG ANTAGONISM; DRUG BLOOD LEVEL; DRUG DIFFUSION; DRUG EFFICACY; DRUG MECHANISM; DRUG RECEPTOR BINDING; HUMAN; NEUROMUSCULAR BLOCKING; PARALYSIS; ADOLESCENT; ADULT; ANESTHETIC RECOVERY; CHEMICALLY INDUCED DISORDER; CHILD; CLINICAL TRIAL; METHODOLOGY; REVIEW;

EID: 67650139017     PISSN: 03759393     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (15)

1. Debaene B, Plaud B, Dilly MP, Donati F. Residual paralysis in the PACU after a single intubating dose of nondepolarizing muscle relaxant with an intermediate duration or action. Anesthesiology 2003;98:1042-1048 (Pubitemid 36520189)
2. Eriksson LI. The effects of residual neuromuscular blockade and volatile anesthetics on the control of ventilation. Anesth Analg 1999;89:243-251 (Pubitemid 29293343)
3. Arbous MS, Meursiong AEE, van Kleef JW, de Lange J, Spoormans H, Touw P et al. Impact of anesthesia management characteristics on severe morbidity and mortality. Anesthesiology 2005;102:257-268 (Pubitemid 40189072)
4. Grayling M, Sweeney BP. Recovery from neuromuscular blockade: a survey of practice. Anaesthesia 2007;62:806-809
5. Eriksson LI. Evidence-based practice and neuromuscular monitoring: it's time for routine quantitative assessment. Anesthesiology 2003;98:1037-1039 (Pubitemid 36520187)
6. Beemer GH, Bjorksten AR, Dawson PJ, Dawson RJ, Heenan PJ, Robertson BA Determinants of the reversal time of competitive neuromuscular block by anticholinesterases. Br J Anaesth 1991;66:469-475
7. Loftsson T, Duchene D. Cyclodextrins and their pharmaceutical applications. Int J Pharm 2007;329:1-11. (Pubitemid 44937538)
8. Brewster ME, Loftsson T. The use of chemically modified cyclodextrins in the development of formulations for chemical delivery systems. Pharmazie 2002;57:94-101. (Pubitemid 34151525)
9. Gijsenbergh F, Ramael S, Houwing N, van Iersel T. First human exposure of Org 25969, a novel agent to reverse the action of rocuronium bromide. Anesthesiology 2005;103:695-703. (Pubitemid 41415517)
10. Blobner M, Eriksson L, Scholz J, Hillebrand, Pompei L. Sugammadex (2 mg/kg) significantly faster reveres shallow rocuronium-induced neuromuscular blockade compared to neostigmine (50 Ig/kg). Eur J Anaesthesiol 2007;24(Suppl 39):126-136
11. Jones RK, Caldwell JE, Brull SJ, Soto RG. Reversal of profound rocuronium induced blockade with sugammadex a randomized comparison with neostigmine. Anesthesiology 2008;109:816-824
12. Heier T, Caldwell JE. Rapid tracheal intubation with large dose rocuronium: a probability based approach. Anesth Analg 2000;90:175-179 (Pubitemid 30022992)
13. Lee C, Jahr JS, Candiotti K, Warriner V, Zornow MH. Reversal of profound rocuronium NMV with sugammadex is faster than recovery from succinylcholine. Anesthesiology 2007;107:A988.
14. Vanacker BV, Vermeyen KM, Struys MRF, Rietbergen H, Vandermeersch E, Saldien V et al. Reversal of rocuronium induced neuromuscular block with the novel drug sugammadex is equally effective under maintenance anaesthesia with propofol or sevoflurane. Anesth Analg 2007;104:563-568 (Pubitemid 46309874)
15. Plaud B, Meretoja O, Hofrnockel R, Raft J, Stoddart PA, van Kuijk JHM et al. Reversal of Rocuronium-induced Neuromuscular Blockade with Sugammadex in Pediatric and Adult Surgical Patients. Anesthesiology 2009;110:284-294